+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Germany Biosimilar Monoclonal Antibodies Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2024

  • ID: 4840561
  • Report
  • Region: Germany
  • 80 pages
  • Infinium Global Research
UP TO OFF
until Dec 31st 2019
1 of 2
The country research report on Germany biosimilar monoclonal antibodies market is a customer intelligence and competitive study of the Germany market. Moreover, the report provides deep insights into demand forecasts, market trends, and, micro and macro indicators in the Germany market. Also, factors that are driving and restraining the biosimilar monoclonal antibodies market are highlighted in the study. This is an in-depth business intelligence report based on qualitative and quantitative parameters of the market. Additionally, this report provides readers with market insights and detailed analysis of market segments to possible micro levels. The companies and dealers/distributors profiled in the report include manufacturers & suppliers of biosimilar monoclonal antibodies market in Germany.

Segments Covered
The report on Germany biosimilar monoclonal antibodies market provides a detailed analysis of segments in the market based on application, and drug class.

Segmentation based on Application
  • Diagnostic Applications
  • MAbs in Biochemical Analysis
  • Pregnancy
  • Cancers
  • Hormonal disorders
  • Infectious diseases
  • MAbs in Diagnostic Imaging
  • Cardiovascular diseases
  • Deep vein thrombosis (DVT)
  • Atherosclerosis
  • Cancers
  • Bacterial infections
  • Therapeutic Applications
  • MAbs as Direct Therapeutic Agents
  • MAbs as Targeting Agents in Therapy
  • Protein Purification
Segmentation based on Drug Class
  • Rituximab
  • Infliximab
  • Abciximab
  • Trastuzumab
  • Adalimumab
  • Bevacizumab
Highlights of the report

The report provides detailed insights into:
1) Demand and supply conditions of biosimilar monoclonal antibodies market
2) Factor affecting the biosimilar monoclonal antibodies market in the short run and the long run
3) The dynamics including drivers, restraints, opportunities, political, socioeconomic factors, and technological factors
4) Key trends and future prospects
5) Leading companies operating in biosimilar monoclonal antibodies market and their competitive position in Germany
6) The dealers/distributors profiles provide basic information of top 10 dealers & distributors operating in (Germany) biosimilar monoclonal antibodies market
7) Matrix: to position the product types
8) Market estimates up to 2024

The report answers questions such as:
1) What is the market size of biosimilar monoclonal antibodies market in Germany?
2) What are the factors that affect the growth in biosimilar monoclonal antibodies market over the forecast period?
3) What is the competitive position in Germany biosimilar monoclonal antibodies market?
4) What are the opportunities in Germany biosimilar monoclonal antibodies market?
5) What are the modes of entering Germany biosimilar monoclonal antibodies market?
Note: Product cover images may vary from those shown
2 of 2
1. Report Overview
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches

2. Executive Summary

3. Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.2.4. Challenges
3.3. PEST-Analysis
3.4. Porter's Diamond Model for Germany Biosimilar Monoclonal Antibodies Market
3.5. Growth Matrix Analysis
3.6. Competitive Landscape in Germany Biosimilar Monoclonal Antibodies Market

4. Germany Biosimilar Monoclonal Antibodies Market by Application
4.1. Diagnostic Applications
4.1.1. MAbs in Biochemical Analysis
4.1.1.1. Pregnancy
4.1.1.2. Cancers
4.1.1.3. Hormonal disorders
4.1.1.4. Infectious diseases
4.1.2. MAbs in Diagnostic Imaging
4.1.2.1. Cardiovascular diseases
4.1.2.2. Deep vein thrombosis (DVT)
4.1.2.3. Atherosclerosis
4.1.2.4. Cancers
4.1.2.5. Bacterial infections
4.2. Therapeutic Applications
4.2.1. MAbs as Direct Therapeutic Agents
4.2.2. MAbs as Targeting Agents in Therapy
4.3. Protein Purification

5. Germany Biosimilar Monoclonal Antibodies Market by Drug Class
5.1. Rituximab
5.2. Infliximab
5.3. Abciximab
5.4. Trastuzumab
5.5. Adalimumab
5.6. Bevacizumab

6. Company Profiles
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll